secwatch.observer — SEC 8-K summary
======================================

Issuer:     Praxis Precision Medicines, Inc. (PRAX)
CIK:        0001689548
Form:       8-K
Filed at:   2024-09-03T23:59:59+00:00
Accession:  0001104659-24-096035
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Praxis Precision Medicines announces positive topline results from EMBOLD study of relutrigine in SCN2A/SCN8A DEE
--------------------------------------------------------------------------------

- Placebo-adjusted reduction of 46% in countable motor seizures for relutrigine-treated patients.
- 5 of 16 randomized patients achieved 28-day seizure-free status on relutrigine vs. none on placebo.
- Relutrigine was generally safe and well tolerated; no patients discontinued due to adverse events.
- Eight patients completed ≥1 OLE period with median motor seizure reduction of 75%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689548/000110465924096035/0001104659-24-096035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689548/000110465924096035/tm2423220d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-096035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer